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ABSTRACT
The aim of this study was to examine if the liver damage caused by CCl4 in combination with kava (Piper methysticum) could
be alleviated via coadministration of sesame lignans. Six groups of male Sprague-Dawley rats were fed with corn oil as a control,
kava only, kava plus sesame lignans, CCl4 only, CCl4 plus kava, and CCl4 plus kava plus sesame lignans, respectively. Body weight,
diet intake, animal behavior, and serum activities of alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP) were recorded along with the course. Four weeks later, organ weights and histopathological data including
liver steatosis and fibrosis were obtained after sacrifice. At day 28, both the diet intakes and body weights of rats decreased, and
their relative liver weights increased considerably in all three CCl4 -treated groups compared to the control group. In accord with
the levels of pathological steatosis and fibrosis, the liver damage caused by CCl4 was somewhat worse when kava extract was coingested, but significantly attenuated when sesame lignans were coadministrated. No detectable liver damage was observed in the
kava or kava plus sesame lignan group. The protective effect of sesame lignans against liver injury caused by CCl4 with or without
kava extract was also observed in the relative activities of plasma ALT, AST and ALP. It is concluded that sesame lignans significantly alleviate liver damage of rats caused by carbon tetrachloride with or without kava. The potential risk of kava’s hepatotoxicity
can be greatly circumvented and the applications of kava may be further extended by coadministration of sesame lignans.
Key words: hepatoprotection, kava (Piper methysticum), sesame lignan, sesamin, sesamolin

Introduction
Kava (Piper methysticum) has been used in Pacific
islands as a medicinal and ceremonial plant for centuries. Conventionally, the rhizome of kava is used to
prepare beverages, extracts, capsules, tablets, and topical
solutions. In the past two decades, kava was introduced worldwide as an herbal tranquilizer and used
as a dietary supplement for anxiety disorders. Effective dosages of kava extract showed relative minor side
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effects, such as drowsiness, dizziness and headaches that
were commonly reported for patients taking benzodiazepine anxiolytics. Unlike brand medications currently
used, no tolerance, physical dependence and withdrawal
symptoms were observed for the long-term utilization of kava extract (1-8). Extensive searches in databases, such as EMBASE, MEDLINE, AMED, CISCOM,
Central/CCTR, and CCDANCTR, suggested a significant effect towards a reduction of the total score of the
Hamilton Anxiety scale in patients receiving kava extract
compared with those receiving placebo (9). The adverse
effects reported in a Cochrane review of kava as a treatment of anxiety were mild, transient and infrequent (10).
Nevertheless, allergic responses and hepatic toxicities
have been noted.
More than 68 cases of suspicious kava hepatotoxicity have been documented since 1998. Some of
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the cases were severe and led to hepatic failure, such
that the patients had to be rescued by liver transplantation. Consequently, kava based herbal products were
either labeled with warning or temporarily banned in
the United States and some European countries. Several
possibilities have been proposed for the liver injury
induced by kava products, including allergy to kava
extract (11), insufficient activities of cytochrome P450related gene products (such as CYP2E1) in patients (12,13),
overdose and/or prolonged treatment (14), co-ingestion of
other medications, and toxic alkaloids in leaf/stem (not
found in root for making extracts).
Sesame seeds and sesame oil have long been used
as health foods in Asia to increase energy and to prevent
aging. It has been known that sesame oil possesses excellent antioxidant activities(15), which may be attributed to
its abundant lignans, such as sesamin and sesamolin (16).
Sesame lignans were found to suppress lipid peroxidation in erythrocytes (17), to inhibit intestinal absorption
of cholesterol and hepatic 3-hydroxy-3-methylglutaryl
CoA reductase activity(18), to prevent chemically induced
mammary cancer (19), to inhibit D5-desaturase and chain
elongation of C18 fatty acids (20), to protect hypoxic
neuronal and PC12 cells by suppressing ROS generation and MAPK activation(21), to enhance the antihypertensive effect (22), and to enhance liver detoxification of
carbon tetrachloride and ethanol(23,24).
In the present study, we aimed to examine if the
liver damage caused by ingesting kava of the highest
recommended concentration (240 mg/kg) under a liverinjuring condition could be alleviated via coadministration of sesame lignans. A liver-injuring condition in rats
was mimicked by treatment of CCl4. Liver damage of rats
fed with various combinations of kava extract, sesame
lignans and CCl4 was evaluated by morphological and
pathological liver changes as well as serum activities of
alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP).

Materials and methods
I. Reagents
Kava root extract was a gift from Yushing Biotech
Company (Taichung, Taiwan, R.O.C.). As revealed by
HPLC analysis, compositions of the kava root extract
(mainly kava ketones) used in this study was essentially
identical both qualitatively and quantitatively to that
of a commercial product available in the United States.
Sesame lignans (mainly sesamin and sesamolin) were
purified from sesame oil as described previously(25).
Purity of sesame lignans (sesamin and sesamolin) was
also verified by HPLC chromatogram. Carbon tetrachloride, corn oil and chemicals were purchased from Sigma
unless specified.

II. Animals
Male Sprague-Dawley rats initially weighing
220-260 g were obtained from the Animal Resource
Center, National Science Council (Taipei, Taiwan,
R.O.C.) and acclimated to the animal facility with free
access to drinking water and standard rodent chow
(Fwusow Ind. Corp., Taichung) at 22°C under a 12-h
light/12-h dark cycle for 1 week before starting the
experiment. The study protocols and care administered
to the animals were approved by the institutional laboratory animal care and use committee.
III. Experimental Design
Six groups of animals, named control, Kava, K+S,
CCl4, C+K, and C+K+S, were included in this study,
representing treatment with corn oil as a control, kava
only, kava plus sesame lignans, CCl4 only, CCl4 plus
kava, and CCl4 plus kava plus sesame lignans, respectively. From day 1 to day 28, kava extract and sesame
lignans (240 and 30 mg/kg body weight) were orally
administrated to animals daily while CCl4 (20% CCl4/
corn oil) was gavaged (0.5 mL/kg body weight) twice
a week in a 2-day interval (Monday and Thursday) 5 h
prior to administration of kava extract and/or sesame
lignans if applicable. The control group was treated with
corn oil and fed with rodent chow diet.
Body weight, diet intake and animal behavior were
recorded daily. Blood samples were withdrawn from tail
vein at 7, 14, 21, and 28 days after the first gavage, and
serum samples were isolated for ALT, AST and ALP
assessments. On day 28, rats were executed under anesthesia with diethyl ether and the order of execution was
randomized among the groups. Liver and spleen tissues
were immediately processed as described below in the
Histology section.
IV. Serum Analyses
Serum samples were obtained from blood by centrifugation at 1000 ×g for 10 min at 4°C. Serum biochemical
marker assay kits for liver, including ALT, AST and ALP,
were purchased from Roche (Roche Diagnostics) and
assayed according to International Federation of Clinical
Chemistry (IFCC) reference procedures on 7600 Clinical
Analyzer (Hitachi)(26).
V. Histology
The liver and other organs were dissected, weighed,
and fixed in 10% buffered formalin. Tissue samples
were embedded in paraffin and cut at 4 microns. Tissue
sections were deparaffinized through xylene and graduated alcohol series to water and stained with hematoxylin and eosin (H & E) for evaluation using a standard
light microscope. The consecutive sections were stained
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with Masson’s trichrome for assessment of fibrosis (27). A
semiquantitative evaluation for histological features was
carried out randomizedly and blindly by a pathologist to
the treatment groups and assessed the grades of tissue
inflammation, fatty accumulation, and hepatotic fibrosis.
Liver steatosis was graded on a three-point scale: 1+,
hepatocytes in the area less than 33% of the lobules
showed fatty accumulation, 2+, between 33 and 66% and
3+, for more than 66% hepatocytes. The criteria used for
scoring fibrosis severity were as follows: 0, normal; 1+,
fibrosis present (collagen fiber present that extends from
portal triad or central vein to peripheral region); 2+,
mild fibrosis (the collagen fiber present with extension
without compartment formation); 3+, moderate fibrosis
(the collagen fiber present with some pseudo lobe formation); and 4+, severe fibrosis (the collagen fiber present
with thickening of the partial compartments and frequent
pseudo lobe formation).
VI. Statistic Analysis
Data were analyzed by one-way analysis of variance
(ANOVA) using SAS general linear models program.
Duncan’s multiple tests were used to determine the
differences among groups. Student’s t-test was used
in the two-group comparison. Values were expressed
as mean ± SEM. Group means were considered to be
significantly different at p < 0.05 as determined by the
protective least significant difference technique when the
ANOVA indicated an overall significant treatment effect.

Results
The average daily food intakes were 36.2, 35.2,
37.7, 31.0, 29.7, and 31.9 g/day in the control, Kava, K+S,
CCl4, C+K, and C+K+S groups, respectively. Apparently, treatment of CCl4 slightly affected the daily diet
intakes of animals as observed in CCl4, C+K and C+K+S
groups. Body weight changes of animals in these six
groups were shown in Table 1. There were no significant
differences in body weights among groups before introducing the supplements (day 0). In contrast, average body
weights of animals in CCl4, C+K and C+K+S groups at
day 28 were significantly lower than those in the control,
Kava and K+S groups (Table 1). Among the three CCl4 treated groups, food intake and body weight of animals
in the C+K+S group (supplemented with sesame lignans)
were evidently higher than those in the other two groups
(supplemented without sesame lignans). Similar to
animals in the control, Kava and K+S groups, animals in
the C+K+S group looked active while those in the CCl4
and C+K groups looked unhealthy with much less movement. The access of drinking water showed no differences among groups, except CCl4 -treated rats which
increased water assess slightly on the days gavaged with
CCl4 (data not shown).

Mean relative liver weights of animals in CCl4, C+K
and C+K+S groups increased to 142, 149 and 146% over
the relative liver weight in the control group and demonstrated statistic significances (Table 1). Though the relative
liver weights of animals in Kava and K+S groups increased
slightly compared to that in the control group, the statistics
showed no differences. As compared to the CCl4 group,
the C+K and C+K+S groups showed significant reductions
in relative liver weights. Treatment of CCl4 resulted in the
elevations of relative spleen weights of animals in CCl4,
C+K and C+K+S groups compared to those in the control,
Kava and K+S groups that showed no significant differences among their relative spleen weights.
Animals fed with kava extract with or without
sesame lignans did not possess obvious morphological and pathological liver changes in comparison with
the control group (Figure 1A and 1B, a, b and c). As
compared to the normal liver of animals in the control
group, the injured liver of animals in the CCl4 group
showed concave light yellowish surface and swelling
in size (data not shown), and the tissue section revealed
lymphocytes infiltration in the central vein (Figure 1A,
d). The hepatocytes were also necrotic and swelling.
Fatty degeneration and cytoplasmic vascuolization were
obvious in the central and mid-zone. Fibrotic injuries
were observed in the CCl4 -treated liver by collagen accumulation and fiber extension in H&E (Figure 1A, d) and
Masson’s trichrome (Figure 1B, d) staining biopsies. The
histopathological examination of liver morphological
changes and damages induced by CCl4 administration
demonstrated evident liver steatosis (scored 2+~3+) and
fibrosis (scored 2+~3+). Concave light yellowish surface
and swelling in size were also observed in the liver of
animals in the C+K group. The liver injuries observed
in the C+K group was similar to those observed in the

Table 1. Body weight, relative liver and spleen weight of CCl4 treated rats with or without the gavage of Kava extract and sesame
lignans for 4 weeks
Group

Body weight
(g)

Relative organ weight
(g/100g of BW)
Liver

Spleen

Control

165 ± 13

3.5 ± 0.2

0.23 ± 0.02

Kava

176 ± 24

4.0 ± 0.2

0.22 ± 0.03

K+S

173 ± 25

4.1 ± 0.4

0.20 ± 0.03

CCl4

107 ± 8**

5.7 ± 0.6**

C+K
C+K+S

**

99 ± 33
126 ± 27

*, #

0.27 ± 0.03

**, #

0.31 ± 0.09

**, #

0.30 ± 0.04

5.2 ± 0.5
5.1 ± 0.5

Values are means ± SEM, n = 4 for controls and n = 7 to 8 for others.
* Significantly different from the control group, *p < 0.05, **p < 0.01.
# Significantly different from the CCl4 group, #p < 0.05. The treatment
protocols are described in details in Experimental design section.
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CCl4 group; no further severer damages existed (Figure
1A and 1B, e). In contrast, coadministration of sesame
lignans in the C+K+S group rescued the liver fibrosis
completely (scored 0-1+) and attenuated CCl4 -induced
fatty accumulation almost completely (scored 0-1+)
(Figure 1A and 1B, f).
Figure 2 shows time courses of activity changes in
plasma ALT, AST and ALP after drug administrations.
With the addition of CCl4, plasma ALT and AST activities
increased gradually while all other groups maintained at
the background levels. ALP levels markedly declined with
time in the control, Kava, K+S, and C+K+S groups, while

were more reluctant to fall in the CCl4 and C+K groups.
On day 28, the plasma ALT, AST and ALP activities of
the CCl4 group increased to 270, 490 and 293% of those
in the control group, respectively. Kava alone or in combination with sesame lignans had no effect on the serum
levels of these three enzymes. In the presence of CCl4,
kava extract did not significantly enhance or reduce ALT,
AST and ALP levels as compared with those in the CCl4
group. Coadministration of sesame lignans in the C+K+S
group greatly reduced ALT, AST and ALP activities to 57,
62 and 61% of those in the CCl4 group, though still higher
than those in the control group.

(A)

a

b

c

d

e

f

a

b

c

d

e

f

(B)

figure 1. Effects of kava extract and sesame lignans on CCl4 -induced liver damage in SD rats: (a) control group treated with corn oil 0.5 mL/kg
body weight, (b) animals treated with 240 mg/kg body weight kava extract, (c) animals treated with 240 mg/kg body weight kava extract and
30 mg/kg body weight sesame lignans, (d) animals treated with CCl4, (e) animals treated with CCl4 and 240 mg/kg body weight kava extract,
and (f) animals treated with CCl4, 240 mg/kg body weight kava extract and 30 mg/kg body weight sesame lignans. (A) Hematoxylin/eosin stain,
(B) Masson stain; magnification 200×. The regions of lymphocyte infiltration and necrosis are labeled with arrowheads and arrows, respectively.
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figure 2. Time courses of ALT (A), AST (B) and ALP (C) activities in plasma of SD rats of the six groups (control, Kava, K+S, CCl4,
C+K, and C+K+S) as described in Figure 1. Values are means ± SEM,
n = 4 for control and n = 7 to 8 for others. *Significantly different
from the control group ( p < 0.05). #Significantly different from the
CCl 4 group ( p < 0.05). The treatment protocols are described in
details in Experimental design section.

vitro studies have shown that kava lactones, the active
principles of kava extracts, inhibited a variety of human
CYP isoforms, while 28 days of kava supplementation only affected CYP2E1 phenotype in a clinical trial,
and caused no elevations in serum liver enzymes(12). It
seems that kava does not directly cause detectable liver
injury, but may possibly raise metabolic burden of liver
and enhance liver injury in the coexistence of other
liver-damaging factors. If the unfavorable factors could
be counteracted by coadministration of liver-protecting
agents, consumption of kava may not lead to the suspicious risk of liver injury. In the present study, in vivo
compensatory or protective effect of sesame lignans
was evaluated under the stress generated by carbon
tetrachloride with or without kava extract. Administration of the highest recommended dosage (240 mg/kg
body weight) or a relatively low dosage (60 mg/kg body
weight; data not shown) of kava extract for 4 weeks did
not result in observable liver damages, though the liver
weight showed slight increase (not statistically significant) which may indicated an increased burden of liver to
metabolize the kava extract.
Carbon tetrachloride is a potent inducer of hepatic
injury and serves in a model protocol to investigate the
possible medication for liver damage. While kava extract
alone did not elicit noticeable liver injury, it did enhance
CCl4 -induced liver damage when coadministrated at a
high dosage. This is concordant with previous fi ndings
showing that patients suffering liver disease or taking
drug products that affect the liver are more vulnerable to liver injuries when coingested a high dosage of
kava (29). Carbon tetrachloride is known to induce oxidative stress by inducing ROS formation, depleting GSH of
phase II enzyme, and reducing antioxidant enzyme and
substrates. Thereafter, free radicals and lipid peroxidation resulted from oxidative stress caused hepatic
damages (30,31). Sesame lignans have been found to
possess superior antioxidative activities and to alleviate
CCl4 - and ethanol-mediated liver injuries (18,23,32). In this
study, detrimental effects of CCl4 with or without kava
extract were significantly alleviated by sesame lignans,
as demonstrated by profound reduction in serological
AST, ALT and ALP activities and greatly improved
histopathology status in liver steatosis and fibrosis.

CONCLUSIONS
DISCUSSION
The adverse effects of kava were often unapparent
and rare, though prolonged and/or overdose kava usage
was a reportedly potential rare but life-threatening risk
factor for hepatotoxicity(28). Causal relationship between
kava and tissue damage has not been directly established, and few literature reports have ever identified
kava components which may affect liver function. In

Our results demonstrate the in vivo hepatoprotective
effects of sesame lignans on the liver damage induced by
carbon tetrachloride in combination with a high dosage
of kava extract. We suggest that the potential risk of
kava’s hepatotoxicity can be greatly circumvented and
the applications of kava may be further extended by
coadministration of sesame lignans. Of course, highlighted precautions in kava applications are indispensable for avoiding overdose or combined usage with other
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drugs that may affect liver severely, and for alerting
patients of liver disease or genetic deficiency.
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